All articles
Can Ozempic® Cause Panic Attacks and Anxiety?
Reading time:
5 min
Weight loss

Get expert guidance and a personalized care plan designed around you.
Comparing Anxiety Side Effects With Other Weight Loss Drugs
Most pharmacological treatments for weight loss and diabetes management come with a spectrum of potential side effects, including psychological ones. Each medication has a unique profile of side effects, which may differ from patient to patient.
Personalized treatment plans are crucial, taking into account the patient's medical history, including predispositions to anxiety or panic disorders.
Similar GLP-1 medications include:
Mounjaro and Zepbound: Both are formulated from the active ingredient tirzepatide. They result in a higher rate of weight loss and a higher incidence of side effects.
Wegovy: This is another semaglutide medication, so its side effect profile is likely to be similar and depends on the dosage.
Explore other medications and consult your health provider to identify your best option.
More On Managing Side Effects On Ozempic
While the potential link between Ozempic® and anxiety warrants further investigation, it's important to understand the interplay between chronic diseases like obesity and diabetes and mental health. Whether anxiety arises as a result of these conditions or exists independently, seeking support from healthcare providers is important. Remember, you're not alone in navigating these challenges; treatment options are available to help manage symptoms and improve your quality of life.
If you want to get started on Ozempic® or need more guidance on managing your overall health on weight loss medications, consider Mochi Health as your comprehensive solution. Find out if you are eligible for our program today.
References:
Tobaiqy, M., & Elkout, H. (2024). Psychiatric adverse events associated with semaglutide, liraglutide and tirzepatide: a pharmacovigilance analysis of individual case safety reports submitted to the EudraVigilance database. International Journal of Clinical Pharmacy, 46(2), 488–495. https://doi.org/10.1007/s11096-023-01694-7
Nakhleh, A., & Shehadeh, N. (2021). Hypoglycemia in diabetes: An update on pathophysiology, treatment, and prevention. World Journal of Diabetes, 12(12), 2036–2049. https://doi.org/10.4239/wjd.v12.i12.2036
DeJean, D., Giacomini, M., Vanstone, M., & Brundisini, F. (2013). Patient experiences of depression and anxiety with chronic disease: a systematic review and qualitative meta-synthesis. Ontario Health Technology Assessment Series, 13(16), 1–33
Chen, X., Zhao, P., Wang, W., Guo, L., & Pan, Q. (2024). The Antidepressant Effects of GLP-1 Receptor Agonists: A Systematic Review and Meta-Analysis. The American Journal of Geriatric Psychiatry, 32(1), 117–127. https://doi.org/10.1016/j.jagp.2023.08.010
This post was written by our team of health writers for informational purposes only and does not constitute medical advice. Always consult your doctor or healthcare provider for personalized guidance regarding your health. Ozempic®, Wegovy®, Mounjaro®, and Zepbound® and their delivery device are registered trademarks. Mochi Health is a telehealth clinic that offers prescriptions for these products by medical necessity only as determined by a licensed health provider.
Share this post
Weight loss
More articles















